Combination treatment for relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug (BCD-248) combined with daratumumab for people whose multiple myeloma has come back or stopped responding to previous treatments. The goal is to see if this combination can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with multiple myeloma and it has returned or not responded to treatment.
- You have had 1 to 3 previous treatments for multiple myeloma, including lenalidomide and a proteasome inhibitor.
- You have not been treated with certain drugs like pomalidomide or anti-BCMA/anti-CD3 therapies.
- You are not resistant to daratumumab or similar anti-CD38 drugs.
- You are generally in good health (able to care for yourself) and have no serious heart, lung, or other conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, BCD-264, compared to Darzalex (daratumumab) alone for people with multiple myeloma that has come back or stopped responding to prior treatments. The goal is to see if BCD-264 works better than Darzalex in controlling the cancer.
This trial tests a new treatment called BCD-248 for people whose multiple myeloma has come back or stopped responding to at least two prior treatments. It aims to see if it is safe and effective.
This trial tests a four-drug combination (daratumumab, cabozantinib, pomalidomide, and dexamethasone) for patients with multiple myeloma that is either not responding to initial treatment or has come back for the first time, especially if it is considered high-risk. The goal is to see if this new combination works better than standard options.
This trial tests a combination of two antibody drugs (elotuzumab and daratumumab) plus an oral pill (iberdomide) and a steroid (dexamethasone) for people whose multiple myeloma has come back after treatment. The goal is to see if this new mix works better than what's already available.
This trial tests a new drug (JNJ-79635322) combined with other treatments like daratumumab or pomalidomide for people with multiple myeloma. It aims to see if these combinations are safe and effective for newly diagnosed or previously treated patients.
This trial tests a combination of two approved drugs (lenalidomide and dexamethasone) plus an experimental drug (iberdomide) for people with multiple myeloma that has returned or stopped responding to treatment. It aims to see if this new combination can help control the disease.
Hear when a new Myeloma Multiple trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.